Hazel H Szeto

US Patent:

7541340, Jun 2, 2009

Filed:

Sep 18, 2006

Appl. No.:

11/532764

Inventors:

Hazel H. Szeto - New York NY, US
Shaoyi Liu - Palisades Park NJ, US
Sunghee Cho - Scarsdale NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 38/07
A61K 38/00

US Classification:

514 18, 514 2

Abstract:

The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2is the largest number that is less than or equal to p−1, except that when a is 1, pmay also be 1.

US Patent:

7550439, Jun 23, 2009

Filed:

Jan 21, 2005

Appl. No.:

11/040242

Inventors:

Hazel H. Szeto - New York NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 38/07

US Classification:

514 18, 530330

Abstract:

The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3pis the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 3or 2is the largest number that is less than or equal to p+1, except that when a is 1, pmay also be 1; and (f) at least one tyrosine or tryptophan amino acid.

US Patent:

7576061, Aug 18, 2009

Filed:

Feb 3, 2004

Appl. No.:

10/771232

Inventors:

Hazel H. Szeto - New York NY, US
Kesheng Zhao - Jackson Heights NY, US
Peter W. Schiller - Montreal, CA

Assignee:

Cornell Research Foundation, Inc. - Ithica NY
Institute de Recherches Clinques de Montreal - Montreal, Quebec

International Classification:

A61K 38/07
C07K 5/10

US Classification:

514 18, 530330

Abstract:

The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2a is the largest number that is less than or equal to p+1, except that when a is 1, pmay also be 1.

US Patent:

7704954, Apr 27, 2010

Filed:

May 3, 2004

Appl. No.:

10/838135

Inventors:

Hazel H. Szeto - New York NY, US
Kesheng Zhao - Jackson Heights NY, US
Hugh D. Robertson - New York NY, US
Alex V. Birk - Woodhaven NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 38/07
C07K 5/10

US Classification:

514 18, 530330

Abstract:

The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.

US Patent:

7718620, May 18, 2010

Filed:

Jun 30, 2006

Appl. No.:

11/427804

Inventors:

Hazel H. Szeto - New York NY, US
Kesheng Zhao - Jackson Heights NY, US
Peter W. Schiller - Montreal, CA

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 38/07

US Classification:

514 18, 514 13, 514 14, 514 15, 514 16, 514 17, 530326, 530327, 530328, 530329, 530330, 530331

Abstract:

The invention provides a method of treating or preventing ischemia-reperfusion injury of the kidney in a mammal. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2 a is the largest number that is less than or equal to p, except that when a is 1, pmay also be 1.

US Patent:

7732398, Jun 8, 2010

Filed:

Jun 29, 2006

Appl. No.:

11/427606

Inventors:

Hazel Szeto - New York NY, US
Peter W. Schiller - Montreal, CA

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY
Clinical Research Institute of Montreal - Montreal, Quebec

International Classification:

A61K 38/00
A61K 38/08
A61K 38/12

US Classification:

514 2, 514 9, 514 17

Abstract:

The present invention provides methods for stimulating mu-opioid receptors with agonist peptides in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid residues has a positive charge. The amino acid residue in the first position is a tyrosine or tyrosine derivative. The amino acid in the second position is a D-α-amino acid. The present invention also provides methods of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the peptides.

US Patent:

7781405, Aug 24, 2010

Filed:

Jun 30, 2006

Appl. No.:

11/428188

Inventors:

Hazel H. Szeto - New York NY, US

Assignee:

Cornell Research Foundation - Ithaca NY

International Classification:

A61K 38/07

US Classification:

514 18, 530330

Abstract:

The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3pis the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 3a or 2a is the largest number that is less than or equal to p+1, except that when a is 1, pmay also be 1; and (f) at least one tyrosine or tryptophan amino acid.

US Patent:

7811987, Oct 12, 2010

Filed:

May 1, 2009

Appl. No.:

12/434216

Inventors:

Hazel H. Szeto - New York NY, US
Shaoyl Liu - Palisades Park NJ, US
Sunghee Cho - Scarsdale NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 38/00

US Classification:

514 2

Abstract:

The invention provides a method for reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3 pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2a is the largest number that is less than or equal to p+1, except that when a is 1, pmay also be 1.